Eysz, Inc.

Eysz, Inc.Eysz, Inc.Eysz, Inc.

Eysz, Inc.

Eysz, Inc.Eysz, Inc.Eysz, Inc.
  • Home
  • Blog
  • More
    • Home
    • Blog
  • Home
  • Blog

Transforming Epilepsy Care

Transforming Epilepsy CareTransforming Epilepsy CareTransforming Epilepsy Care
image8
image9
image10
image11
image12

The Disorder

Epilepsy is a chronic, neurological disorder, which has been around for 3000 years, and causes unprovoked, recurrent seizures with impacts ranging from social stigma, isolation, injury, and sudden death.

The Numbers

image13

70 Million

3.4 Million

3.4 Million

People with Epilepsy Worldwide

image14

3.4 Million

3.4 Million

3.4 Million

People with Epilepsy in the USA

image15

150,000

3.4 Million

150,000

New Cases Annually in the USA

The PROBLEM

image16

"Endless" Titration Loop

Physicians rely on self reported seizure data to manage their patient's epilepsy - particularly in determining the right medication and the right dose.  However, studies have shown that this data  is up to 50% accurate.  

image17

Increased Costs while outcomes stagnant

A recent study showed that in the USA, direct costs related to Epilepsy have almost doubled in the last decade to $28B per year, while outcomes have not improved in almost three decades.

The Parents' Perspective

Not only is it difficult for Physicians to understand what is happening outside of the clinic, but it is also difficult for Parents and Patients to be the 'eyes' of the Physicians outside of the clinic.  Hear the perspective of Amy and David - parents of a child diagnosed with seizures.

The solution

Using passive oculometric data from consumer grade eye-tracking systems, our software algorithms have the potential to reliably detect seizures and other neurological 'vital signs'.  By employing machine learning capabilities, we expect our software to be able to predict when a seizure will occur.   

The Potential Benefits

image18

Improving Outcomes

Improving Quality of Life

Improving Quality of Life

By helping physicians get the data they need to make timely medical decisions. 

image19

Improving Quality of Life

Improving Quality of Life

Improving Quality of Life

Getting patients on path to seizure freedom quicker and reducing the burden of tracking seizures.

image20

Reducing Costs

Improving Quality of Life

Reducing Costs

Helping providers and patients reduce the number of costly visits to the hospital.

The Evidence

image21

Preliminary

We recently completed a 30 patient proof-of-concept study which resulted in robust seizure detection of the subtlest seizure type, absence seizures.

Upcoming

In July 2020, we launched an in depth clinical study involving 3 clinical collaborators that have been designated Level 4 by the National Association of Epilepsy Centers to help us collect the data we need to begin improving the accuracy of our software.

Our Team

image22

Rachel Kuperman, MD, Founder & CEO

Rachel Kuperman, MD, Founder & CEO

Rachel Kuperman, MD, Founder & CEO

Neurologist with dual certification in epilepsy and neurology with over 10 years’ experience directing the clinical epilepsy and research programs at UCSF Benioff Children’s Hospital, Oakland

image23

Jit Sarkar, PhD Co-Founder

Rachel Kuperman, MD, Founder & CEO

Rachel Kuperman, MD, Founder & CEO

Leads the algorithm development for Eysz solution. He completed his undergraduate degree in computer science and has deep experience applying machine learning methods. His PhD from UCSD focused on extracting signals from a complex medium.

image24

Parth Amin, Co-Founder

Rachel Kuperman, MD, Founder & CEO

Parth Amin, Co-Founder

Leads our Product Development efforts and GTM Strategy.  Brings 15+ Years Medical Device Experience in Product and Project Management, Product Launch, and Alliances having worked at Siemens Healthineers, Varian, and Omnicell. 

Our Advisors

image25

Robert Fisher, MD, PhD Scientific Advisor

Robert Fisher, MD, PhD Scientific Advisor

Robert Fisher, MD, PhD Scientific Advisor

Dr. Fisher is Maslah Saul MD Professor and Director of the Stanford  Epilepsy Center. He had research awards from the Klingenstein  Foundation, EF, CURE and NIH. He published 160 peer-reviewed articles  and 4 books. He was named 1996-2016 in Best Doctors in America.  Dr. Fisher is Past-President of the American Epilepsy  Society, and has 

Dr. Fisher is Maslah Saul MD Professor and Director of the Stanford  Epilepsy Center. He had research awards from the Klingenstein  Foundation, EF, CURE and NIH. He published 160 peer-reviewed articles  and 4 books. He was named 1996-2016 in Best Doctors in America.  Dr. Fisher is Past-President of the American Epilepsy  Society, and has served on the Board of the ILAE and as Editor-in-Chief  of the Journal, Epilepsia.  His research is on new devices to treat epilepsy.   

image26

Hal Blumenfeld, MD, PhD Scientific Advisor

Robert Fisher, MD, PhD Scientific Advisor

Robert Fisher, MD, PhD Scientific Advisor

Dr. Blumenfeld's clinical and research work focuses on epilepsy, cognition and brain  imaging. He directs Yale's Clinical Neuroscience Imaging Center (CNIC), a  new multi-disciplinary core facility for innovative study and treatment  of brain disorders. Teaching activities include a textbook titled  Neuroanatomy Through Clinical Cases, Sinauer Assoc., Publ. 2002, 2010. 

image27

Peter Milford, PhD Technical Advisor

Robert Fisher, MD, PhD Scientific Advisor

Peter Milford, PhD Technical Advisor

Dr. Milford has over 15 years experience in developing high technology instrumentation. He was CTO of Eyefluence, which was developing the next generation eye-tracking wearable technology,  up until October 2016, when purchased by Google. He  continued to develop eye interaction and eye tracking for augmented reality (AR) and virtual real

Dr. Milford has over 15 years experience in developing high technology instrumentation. He was CTO of Eyefluence, which was developing the next generation eye-tracking wearable technology,  up until October 2016, when purchased by Google. He  continued to develop eye interaction and eye tracking for augmented reality (AR) and virtual reality (VR) headsets.  He now serves as the President of Parallel Rules consulting firm.  

image28

Steve Duddy Business Advisor

Nicolle Napier-Ionascu, PsyD Scientific Advisor

Peter Milford, PhD Technical Advisor

Steve brings 30+ years of leadership and strategy experience in the Medical Device industry.  He has held a variety of leadership roles in various cross functional areas.  Most recently, he is serving as the President and Chairman of Nuvolase Inc., which has developed the gold standard for Onychomycosis.  Under his leadership, the company

Steve brings 30+ years of leadership and strategy experience in the Medical Device industry.  He has held a variety of leadership roles in various cross functional areas.  Most recently, he is serving as the President and Chairman of Nuvolase Inc., which has developed the gold standard for Onychomycosis.  Under his leadership, the company has grown in revenues, remained debt-free, and has expanded into new markets. 

image29

Nicolle Napier-Ionascu, PsyD Scientific Advisor

Nicolle Napier-Ionascu, PsyD Scientific Advisor

Nicolle Napier-Ionascu, PsyD Scientific Advisor

Practicing neuropsychology for over 12 years. She is also the head Neuropsychologist in the Epilepsy department at UCSF Benioff Children’s Hospital Oakland.  

Board

image30

Randy Berholtz JD, MBA

Randy Berholtz JD, MBA

Randy Berholtz JD, MBA

Randy leverages his corporate experience, where he has held roles as a corporate and business development executive and as general counsel, to help nurture over 25 startups in healthcare from funding, to serving as a board of director to corporate and business development and strategic initiatives.  He currently services as a Partner for 

Randy leverages his corporate experience, where he has held roles as a corporate and business development executive and as general counsel, to help nurture over 25 startups in healthcare from funding, to serving as a board of director to corporate and business development and strategic initiatives.  He currently services as a Partner for Ventac Partners and a Senior Advisor for Mesa Partners.  He is also a parent of a child with epilepsy.

image31

Erik Janssen, PhD

Randy Berholtz JD, MBA

Randy Berholtz JD, MBA

Erik Janssen is the Head of Digital Transformation Immunology and Neurology at UCB Pharma, the global leaders in the field of epilepsy research and medicine development. Erik brings 25+ years of global executive experience in pharma and digital health innovation. In his current role, Erik leads an international mission whose focus is on i

Erik Janssen is the Head of Digital Transformation Immunology and Neurology at UCB Pharma, the global leaders in the field of epilepsy research and medicine development. Erik brings 25+ years of global executive experience in pharma and digital health innovation. In his current role, Erik leads an international mission whose focus is on investigating technology solutions with potential to make a meaningful difference to the lives of people living with neurological conditions like epilepsy and Parkinson’s Disease.

Drop us a line with any questions, comments, or inquiries you may have or if you want to simply stay in touch.



Copyright © 2020 Eysz, Inc. - All Rights Reserved.

Powered by GoDaddy